The combination of a strong beat, raised guidance, and first-ever share repurchase program signals management confidence in sustained growth. Monitor MACI biopsy/implant trends and progress on UK MHRA submission for further upside catalysts.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $47.61entry
- T+1 · 4mo ago −3.47%α −4.17% · $45.96
- T+5 · 3mo ago −6.01%α −9.63% · $44.75
- T+20 · 3mo ago −13.51%α −17.47% · $41.18
- T+60 · 25d ago −10.67%α −13.13% · $42.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vericel reported Q2 2026 revenue of $77.5M (+22% YoY), beating consensus of $72.7M, and GAAP EPS of $0.04 vs -$0.01 a year ago and consensus -$0.03. The company raised full-year 2026 revenue guidance to $330-340M and authorized a $200M share repurchase program, its first ever.
Key Financial Metrics
Key Facts
- Total revenue $77.5M, up 22% YoY, vs consensus $72.7M
- GAAP diluted EPS $0.04 vs -$0.01 YoY and consensus -$0.03
- Full-year 2026 revenue guidance raised to $330-340M from $326-336M
- Board authorized $200M share repurchase program
- MACI revenue grew 23% to $65.5M; Burn Care revenue grew 22% to $12.0M
- Net income of $2.2M vs net loss of $0.6M in Q2 2025
- Free cash flow of $14.3M in Q2; $29.4M in H1 2026
- Cash and investments of $227M, no debt
Financial Impact
Revenue beat by ~$4.8M (6.5%) vs consensus; EPS beat by $0.07 vs consensus; guidance raised by $4M at midpoint; $200M buyback represents ~8% of market cap
Risk Factors
- Execution risk on scaling manufacturing at new Burlington facility
- Regulatory and commercial uncertainty for MACI UK approval
- Potential impact of healthcare policy changes on reimbursement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-050815 |
| Document: vcel-20260730.htm | 0001628280-26-050815 |
| Document: 0001628280-26-050815-index-headers.html | 0001628280-26-050815 |
| Document: 0001628280-26-050815-index.html | 0001628280-26-050815 |
| Document: 0001628280-26-050815.txt | 0001628280-26-050815 |
| 8-K Data (Synthetic) | 0001628280-26-050815 |
Track record
30 reports on VCEL
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 1/10 Entry $57.42 Now $57.48 +0.10% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $54.62 Now $57.48 +5.24% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers